alexa Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
Microbiology

Microbiology

Journal of Antivirals & Antiretrovirals

Author(s): Limin M, Johnsen N, Hellstrom WJ

Abstract Share this page

Abstract IMPORTANCE OF THE FIELD: Erectile dysfunction (ED) is a common sexual problem, affecting up to half of men over 50 years of age. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil and vardenafil) are currently the first-line treatment option presented to patients with ED. There exists a significant number of men who remain dissatisfied with the available therapies and are either unable to achieve their therapeutic goals or unwilling to tolerate adverse side effects. Therefore, development of novel PDE5 inhibitors with enhanced selectivity, faster onset of action, increased potency and improved tolerability is desirable. AREAS COVERED IN THIS REVIEW: Preclinical and clinical studies of avanafil, a new oral PDE5 inhibitor being investigated for the treatment of ED. Data were obtained by searching for all English peer-reviewed articles on Medline and any related abstracts presented on avanafil at major international congresses. WHAT THE READER WILL GAIN: An understanding of the pharmacokinetic and pharmacodynamic characteristics of avanafil and insight into the drug's clinical efficacy and safety profile. TAKE HOME MESSAGE: We propose that avanafil, which displays enhanced selectivity, faster onset of action, and a favorable side-effect profile relative to currently available PDE5 inhibitors, may offer an alternative first line treatment option for men with ED. This article was published in Expert Opin Investig Drugs and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords